Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for Dacarbazine (compound)

Name: Dacarbazine
PubChem Compound ID: 5281007
Description: An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564)
Molecular formula: C6H10N6O
Molecular weight: 182.183 g/mol
Dacarbazine; 4342-03-4; CHEBI:4305; 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide; 5-(3,3-dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide; DTIC-Dome (TN); Imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazeno)-
Name: Dacarbazine
Name (isomeric): DB00851
Drug Type: small molecule
Description: An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564)
ICDMT; Dtic-Dome; ICDT; Imidazole Carboxamide; Biocarbazine R; Dacarbazino [INN-Spanish]; DTIC; DTIE; DIC; Dacarbazinum [INN-Latin]
Brand: Deticene
Category: Antineoplastic Agents, Antineoplastic Agents, Alkylating
CAS number: 4342-03-4
Indication: For the treatment of metastatic malignant melanoma. In addition, dacarbazine is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other antineoplastic agents.
Dacarbazine is a synthetic analog of naturally occurring purine precursor 5-amino-1H-imidazole-4-carboxamide (AIC). After intravenous administration of dacarbazine, the volume of distribution exceeds total body water content suggesting localization in some body tissue, probably the liver. Its disappearance from the plasma is biphasic with initial h...
show more »
Mechanism of Action: The mechanism of action is not known, but appears to exert cytotoxic effects via its action as an alkylating agent. Other theories include DNA synthesis inhibition by its action as a purine analog, and interaction with SH groups. Dacarbazine is not cell cycle-phase specific.
Absorption: Erratic, slow and incomplete
Protein binding: Less than 5%
Biotransformation: Hepatic
Route of elimination: Dacarbazine is subject to renal tubular secretion rather than glomerular filtration. In man, dacarbazine is extensively degraded. Besides unchanged dacarbazine, 5-aminoimidazole -4 carboxamide (AIC) is a major metabolite of dacarbazine excreted in the urine.
Half Life: 5 hours
Toxicity: LD50=350mg/kg (orally in mice)
Affected organisms: Humans and other mammals
Drug interaction:
ThiabendazoleThe strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Dacarbazine by decreasing Dacarbazine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Dacarbazine if Thiabendazole is initiated, discontinued or dose changed.
TrastuzumabTrastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.